Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Applying pseudoceramide improved skin and hair health.

This study found that long-term hair follicle stem cells originate from embryonic progenitor cells in a niche with reduced Wnt/β-catenin signaling, which is essential for their specification.

This study found hair regrowth in the majority of AA-affected mice and rats treated with diphencyprone, suggesting its potential utility for understanding human alopecia areata and the drug's therapeutic action.

Diphencyprone treatment protocols could be simplified as no harm occurred despite not fully following them.

This article reviews DPCP's use as a topical immunotherapy for alopecia areata and discusses its suggested mechanism, but reports no clinical results.

In this study, 12-Chloracetyl-PPD showed anti-cancer activity by inhibiting cancer cell viability and inducing apoptosis through reactive oxygen species production without harming normal cells.

This study found that the 15-PGDH inhibitor DPP improved endothelial function in hair-related cells exposed to DHT by reducing oxidative stress and enhancing angiogenic capacity.

This study found that diphencyprone is an effective and safe treatment for extensive alopecia areata, especially with long-term therapy and maintenance to reduce relapse risk.

This study found that cPPARγ and dnPPARγ isoforms are differentially expressed in healthy human skin, suggesting that PPARγ modulators may have compartment-specific effects depending on isoform presence.

This study suggests that DPCP treatment can be effective and safe for severe alopecia areata in children, with maintenance therapy potentially reducing relapse rates.

This study found that increased Bcl-2 protein expression after DPCP treatment was associated with hair regrowth in alopecia areata patients, suggesting its role in inhibiting apoptosis.

This study found that the peptide derivative beta-Ala-Pro-Dab-NHbenzyl may reduce wrinkles and sebum production in human skin by inhibiting dipeptidyl peptidase 4, suggesting potential for acne and skin inflammation treatment.

Recognizing IPPP is crucial to prevent misdiagnosis and unnecessary treatments.

This study found that 21 out of 39 patients with alopecia areata experienced more than 50% hair regrowth after six months of DPCP treatment, with better outcomes observed in those treated at 3-week intervals compared to weekly intervals.

This study found that adding PRP to DPCP treatment for severe alopecia areata did not enhance effectiveness compared to DPCP alone.

This source explains that Equine Cushing’s disease, or PPID, in horses is due to the degeneration of brain cells producing dopamine, leading to elevated cortisol levels and characteristic symptoms; it outlines diagnosis methods and emphasizes life-long pergolide treatment to manage the condition.

This study found that home-use diphenylcyclopropenone (H-DPCP) is a cost-effective alternative to office-use for severe alopecia areata, showing similar effectiveness with reduced costs.

This study explored the effects of DPP, a 15-PGDH inhibitor, on human follicle dermal papilla cells damaged by dihydrotestosterone and observed that DPP enhanced wound healing, reduced reactive oxygen species, and increased hair growth in ex vivo human hair follicle cultures.

This study found that topical diphenylcyclopropenone was effective in treating severe alopecia areata but had a high relapse rate and was often accompanied by side effects like eczema and lymphadenopathy.

This review examines experimental and clinical evidence on PDRN, a drug derived from salmon DNA that acts via the adenosine A2A receptor and shows promise for tissue repair and treatment of diabetic foot ulcers in regenerative medicine.

This study found that after 24 weeks of DPCP treatment for alopecia areata, there was a significant increase in new capillaries and hair regrowth detectable by videocapillaroscopy.

This study found that dexamethasone treatment inhibited the inflammatory response and the induction of ornithine decarboxylase activity in mouse skin after TPA application, although the effect on ODC was weaker during the hyperplastic stage.

This review discusses consumers' positive attitudes towards direct-to-consumer pharmaceutical advertising, highlighting its impact on patient engagement despite physicians' mixed opinions on its influence on the doctor-patient relationship.

Among pediatric alopecia areata patients treated with DPCP, this study reported complete hair regrowth in 8.8% and any regrowth in 61.8% after one year, with better outcomes for those with milder initial symptoms and longer treatment durations.

This study found that nanostructured lipid carriers with more soybean phosphatidylcholine provided better skin retention and follicular targeting for diphencyprone compared to other formulations and controls.

This study concluded that both DPCP alone and combined with PRP are effective and safe for treating severe alopecia areata, with no significant difference between the two treatment methods.

This report describes a 60-year-old female with pretibial pruritic papular dermatitis who showed significant improvement of skin lesions after one month of treatment with oral pentoxifylline. The authors highlight the unique clinical and histological features of PPPD and propose pentoxifylline as a potential therapy.

In this report, a 19-year-old Japanese man experienced severe and prolonged urticarial reactions following treatment with diphenylcyclopropenone for alopecia universalis, emphasizing the need for caution with potent sensitizers.

This study found that DPCP immunotherapy effectively treats alopecia areata, identifying factors that influence treatment response and patient satisfaction, which may aid in standardizing the treatment for improved outcomes.

In this study, treatment with DPCP alone was more effective for hair regrowth and presented fewer side effects in chronic extensive alopecia areata compared to combination therapy with DPCP and anthralin.